UH-232

UH-232, or (+)-UH-232, also known as 5-hydroxy-1-methyl-2-(dipropylamino)tetralin methyl ether (5-HMDPTME), is a dopamine and serotonin receptor modulator of the 2-aminotetralin family which was under development for the treatment of schizophrenia but was never marketed. It is taken orally. Contrary to expectations, the drug did not end up producing antipsychotic effects in clinical trials. Instead, it was reported to produce stimulant, hallucinogenic, and psychosis-exacerbating effects.
Wikipedia contributors, "UH-232", Wikipedia, revision 1379545036, retrieved 20 November 2026, source, CC BY-SA 4.0.